Effect of CYP2C19 polymorphism on response to bortezomib-based therapy in multiple myeloma patients

CONCLUSIONS: Polymorphism in CYP2C19 enzyme is likely to have an impact on bortezomib treatment response and peripheral neuropathy. The study suggests the role of pharmacogenetics in personalised treatment of MM.PMID:38561047 | DOI:10.1016/j.amjms.2024.03.022

Source: The American Journal of the Medical Sciences - April 1, 2024 Category: General Medicine Authors: Lavisha Goel Pooja Gupta Lalit Kumar Thirumurthy Velpandian Archana Singh Kalpana Luthra Yogendra Kumar Gupta Source Type: research